The Role of Surgery in Management of Primary Metastatic Endometrial Cancer
- Taylor Hodge 1,2, Monica McGauran 1,2,3, Antonia Jones 1,3, Rosemary McBain 1,3, Simon Hyde 1,2
- Taylor Hodge 1,2, Monica McGauran 1,2,3, Antonia Jones 1,3
- 1Mercy Hospital for Women, Melbourne, Australia.
- 2University of Melbourne, Melbourne, Australia.
- 3Royal Women's Hospital, Melbourne, Australia.
- 0Mercy Hospital for Women, Melbourne, Australia.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Advanced endometrial cancer has a poor prognosis, and its surgical management is understudied. This review examines evidence for surgical cytoreduction and neoadjuvant treatment in primary metastatic endometrial cancer to improve survival outcomes.
Area Of Science
- Gynecologic Oncology
- Surgical Oncology
- Translational Oncology
Background
- Early-stage endometrial cancer has excellent survival with standard surgery.
- Advanced-stage (metastatic) endometrial cancer has a poor prognosis (15-20% 5-year survival).
- Management of primary advanced endometrial cancer is understudied, with limited prospective data.
Purpose Of The Study
- To review current evidence on the surgical management of primary metastatic endometrial cancer.
- To analyze guideline recommendations, cytoreductive surgery, neoadjuvant therapy, and metastasis resection.
- To explore the role of molecular classification in advanced disease.
Main Methods
- Systematic review of current literature and international guidelines.
- Analysis of evidence for primary cytoreductive surgery and neoadjuvant systemic treatment.
- Evaluation of surgical resection of distant metastases and lymph node management.
Main Results
- Hysterectomy and cytoreduction may improve survival in metastatic endometrial cancer, but optimal patient selection is unclear.
- Neoadjuvant systemic therapy followed by surgery is an emerging paradigm.
- Data on molecular features in advanced disease are limited, hindering personalized treatment.
Conclusions
- Further prospective studies are needed to define the role of surgery and neoadjuvant therapy in primary advanced endometrial cancer.
- Integrating molecular profiling into treatment strategies for advanced disease requires further investigation.
- Optimizing surgical cytoreduction and selecting appropriate patients are critical for improving outcomes.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

